metal response element binding transcription factor 2Genealiases: M96 · PCL2 · TDRD19A · dJ976O13.2
Q-omics provides the consensus-scored MTF2 profile across patient tissues and cancer cell-line models. MTF2 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTF2 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, MTF2 RNA expression shows 20,675 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where MTF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTF2 survival associations across molecular data types. MTF2 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTF2 RNA expression–survival associations across cancer types. High MTF2 expression shows unfavorable associations in ACC, LIHC, LGG and KIRC, but favorable associations in UCS and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTF2 RNA expression.
This table summarizes MTF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MTF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTF2 shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, KIRC, STAD and LIHC. The HNSC box plot shows higher MTF2 RNA expression in tumor versus normal tissue (log2 FC = +0.597, t-test p < 0.001).
This table shows molecular features associated with MTF2 in patient tissues and cancer cell lines. In patient samples, MTF2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
